Nanoscope Therapeutics Inc.

Nanoscope Therapeutics Inc. team is in Chicago at Eyecelerator Retina Showcase and excited to receive the Eyecelerator@AA02024 People's Choice Award! Accepting the award for Nanoscope is Dr. Samuel B Barone, Chief Medical Officer (far right) joined on stage by other recipients and moderator Dr. Allen Ho (far left). Thank you to all who selected Nanoscope to receive this recognition. On Sunday, October 20 at American Academy of Ophthalmology #AAO2024 Dr Allen Ho, Chief Medical Advisor of Nanoscope, will present "Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to RP: Two-Year TOPLINE Results from a Phase 2b/3 Randomized, Sham-Controlled Clinical Trial (RESTORE)". The presentation takes place from 2:00-3:15pm CDT in McCormick Place Convention Center, Room S405. For more information about Nanoscope visit our website: nanostherapeutics.com #ophthalmology #retina #retinitispigmentosa #stargardt #GA #AMD #genetherapy Sulagna Bhattacharya Samarendra Mohanty

Nanoscope Therapeutics Inc. will present at the #AAO2024 Annual Meeting taking place October 18-21, 2024 in Chicago, Illinois, and the associated Eyecelerator @ AAO 2024 and Innovate Retina meetings both taking place on October 17th, 2024. Details for the presentations are as follows: Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to RP: Two-Year TOPLINE Results from a Phase 2b/3 Randomized, Sham-Controlled Clinical Trial (RESTORE) Session: Session PA048 (Retina, Vitreous Original Papers) Session Date: Sunday, October 20th, 2024 Session Time: 2:00PM – 3:15 PM CDT (In Person, On Demand) Location: McCormick Place Convention Center, Room S405 Presenter: Allen Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope Therapeutics, Inc. RESTORE is the first-ever RCT to show statistically significant visual acuity improvement in this patient population and a key part of the upcoming BLA submission planned for Nanoscope’s RP program. Session Title: Retina Showcase (Eyecelerator @ AAO 2024) Session Date: Thursday, October 17th, 2024 Session Time: 1:15 – 3:00 PM CDT Location: McCormick Place Convention Center, room E450a Presenter: Samuel B Barone, MD, Chief Medical Officer During his presentation, Dr. Barone will showcase Nanoscope’s next-generation Multi-Characteristic Opsin platform program for patients with geographic atrophy (GA) due to advanced AMD. Session Title: The Future of Retinal Therapeutics (Innovate Retina) Session Date: October 17th, 2024 Session Time: 6:24 PM CDT Location: InterContinental Chicago Magnificent Mile, Grand Ballroom Panelist: Samarendra Mohanty, PhD, President and Chief Scientific Officer Dr. Mohanty will participate in a panel covering the landscape of cutting-edge therapies in development to address retinal diseases. For more information about Nanoscope Therapeutics visit our website: nanostherapeutics.com #ophthalmology #retina #eyecelerator #retinitispigmentosa #stargardt

Today is World Sight Day, making it all the more meaningful for Nanoscope Therapeutics Inc. to announce plans to submit a Biologics License Application (BLA) for our gene therapy MCO-010 to treat Retinitis Pigmentosa based on the regulatory feedback provided in a productive FDA meeting for our clinical program. We plan to commence with submission of a BLA in Q1 2025. In connection with the meeting, the FDA acknowledged Nanoscope's proposed next steps to facilitate a BLA submission for MCO-010 for the treatment of severe vision loss due to RP. Nanoscope outlined its plans for a rolling submission of the MCO-010 BLA for the treatment of severe vision loss due to RP based on its Fast Track Designation. Nanoscope has also completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients and recently announced plans to initiate a Phase 3 registrational trial in Q1 2025. Read the complete press release: https://lnkd.in/gmFv42w2 For more details about Nanoscope Therapeutics and our development pipeline visit our website: nanostherapeutics.com #retinitispigmentosa #worldsightday #stargardt #genetherapy #clinicaltrials Sulagna Bhattacharya Samarendra Mohanty Samuel B Barone Allen Ho

Thanks to BioNTX for inviting Nanoscope Therapeutics Inc. CEO Sulagna Bhattacharya to participate in this week's 2024  iC³ Life Science & Healthcare Innovation Summit. We are proud to be part of the dynamic North Texas bioscience and healthcare community and events like this are a priceless opportunity to connect and exchange experiences with leaders in our industry from the #Dallas area and around the world. #Texas #lifesciences #cellandgenetherapy #biotechnology #Texas

Nanoscope Therapeutics Inc. announces it has acquired a license for the CatCh technology from Max Planck Innovation, the technology transfer organization of the Max Planck Society. Based on research findings from the Max Planck Institute of Biophysics, and the pioneering work of Prof. Ernst Bamberg in the field of optogenetics, this patented technology enhances the light sensitivity of a multi-characteristic opsin (MCO-010, a tri-protein fusion complex including CatCh) developed by Nanoscope as a gene therapy to restore vision in patients suffering from genetically caused visual impairments. Nanoscope's groundbreaking MCO platform is the first optogenetic approach to combine multiple light-sensitive components, the sum of which produces a fusion protein that is sensitive across the visible spectrum at ambient light levels with fast kinetics. Nanoscope has already successfully completed several clinical studies on MCO-010 for the two leading inherited retinal degenerative diseases: retinitis pigmentosa (RP) and Stargardt disease. The company now plans to seek approval for the therapy and expand to broad therapeutic indications. "We are excited to see the enhanced benefits of the MCO platform, which incorporates the CatCh technology from the Max Planck Institute for Biophysics, and offers new hope for restoring vision in those suffering from severe degenerative retinal conditions," said Dr. Samarendra Mohanty, Co-Founder & President of Nanoscope Therapeutics. "Our agreement with Max Planck Innovation allows us to transform groundbreaking scientific discoveries into effective therapeutic solutions. With efficient viral delivery of the most complex bioengineered non-mammalian MCO-010 fusion protein to treat severe degenerative retinal conditions caused by many different genetic mutations, we are on the cusp of treating patients with high unmet needs and sustainably improving their quality of life." Dr. @Mareike Göritz, Patent and Licensing manager at Max Planck Innovation, added: "The advanced properties of CatCh in combination with Nanoscope's proprietary technology make this a very promising approach for gene therapy treatment of retinitis-related visual impairments. We are excited to follow the further development and would be delighted if patients were ultimately to benefit from this innovative approach." The further development and approval pathway for MCO-010 is currently being intensively reviewed. Nanoscope Therapeutics aims to obtain approval and is in discussions with the US Food and Drug Administration (FDA) to explore possible accelerated pathways to market. These efforts could help make the innovative therapy available to patients more quickly, who urgently need new treatment options. For more details read the full press release: https://lnkd.in/gJTjfwei #retinitispigmentosa #retina #stargardts #genetherapy

On this World Retina Day, Nanoscope Therapeutics Inc. is proud to be part of the global retina community’s efforts in raising awareness and driving innovation in retinal care. Our team is dedicated to the development of therapies to restore sight to those with degenerative retinal diseases and driven by our mission to bring the light of hope to people around the world. Shown below are members of the Nanoscope team as they recently welcomed Congressman Jake Ellzey, Arlington City Council Member Rebecca Lively-Boxall, Arlington Economic Development Corporation Executive Director Marty Wieder, AICP, Biotechnology Innovation Organization Government Relations representative Elisabeth (Lizzy) Fox, and other guests for a presentation about Nanoscope’s groundbreaking work and a tour of our Arlington lab and development facility. #worldretinaday #retina

Thank you for choosing our CEO Sulagna Bhattacharya as this year's SPARK Award Winner. Those of us who work with her everyday agree! https://lnkd.in/gwesYvYX

From the European Society of Retina Specialists (EURETINA) Congress in Barcelona all of us at Nanoscope say "Thank You" to the panel of distinguished experts who participated in our Nanoscope Therapeutics Symposium: Optogenetic Therapies for Retinal Degenerative Disease - Clinical Developments and Updates. They included Jordi Monés MD PhD, Arshad M. Khanani, Prof. Paulo Eduardo Stanga, Usha Chakravarthy, MD, Francesco Bandello. We were very pleased to see so many join us to learn about exciting advancements in the field of optogenetics and the hope it brings to our patients around the world who suffer degenerative #retinal diseases Sulagna Bhattacharya Samarendra Mohanty Samuel B Barone Nanoscope Therapeutics Inc. #EURETINA20 #retina #ophthalmology #blindness

Great to partner with eminent clinicians and researchers to bring this transformative therapies to patients with highest unmet need.

We are honored to have 100-week TOPLINE results from our Phase 2b/3 RESTORE Clinical Trial of Nanoscope Therapeutics Inc.'s MCO-010 for Retinitis Pigmentosa to be presented at European Society of Retina Specialists (EURETINA) Congress by Jordi Monés MD PhD, Director of Institut de la Màcula, and Barcelona Macula Foundation. Prof. Monés' presentation will take place Saturday, September 21 at 9:36am CEST in Room 115. In addition to typical measures of efficacy at single time points (primary and key secondary endpoints), Dr. Monés will present the efficacy analysis for best corrected visual acuity (BCVA) in Multi-Characteristic Opsin (MCO-010) treated retinitis pigmentosa patients using the area under the curve (AUC) method that captures treatment benefit over the entire 2-year observation period in RESTORE. For details of the presentation: https://lnkd.in/gGxEt3tS Prof. Jordi Monés (Spain) will also chair a satellite symposium focused on optogenetics therapeutics for IRDs and geographic atrophy. For details of the symposium: https://lnkd.in/gGxEt3tS The Nanoscope management team are in Barcelona to attend the conference and are accessible for meetings. #euretina2024 #retina #clinicaltrials #retinitispigmentosa